Latest Amgen Stories
THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will report its first quarter financial results on Tuesday, April 22, 2014, after the close
SANTA MONICA, Calif., April 11, 2014 /PRNewswire/ -- Kite Pharma, Inc.
THOUSAND OAKS, Calif., April 4, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results from the primary overall survival (OS) analysis of a Phase 3 trial in melanoma, which
Data From Two Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented in Late-Breaking Clinical Trials Session at ACC.14 - Data Add to the Three Pivotal Studies Presented Yesterday THOUSAND
Data From Three Separate Phase 3 Studies of Evolocumab (AMG 145), a PCSK9 Inhibitor, Presented as Featured Clinical Research at ACC.14 THOUSAND OAKS, Calif., March 29, 2014 /PRNewswire/ --
DUBLIN, March 28, 2014 /PRNewswire/ -- Dublin - Research and Markets ( http://www.researchandmarkets.com/research/8zbxmj/investigation) has announced the addition of the
Carl Adams Promoted to Chief Financial Officer and Craig Rostamian Joins as Vice President of Finance LOS ANGELES, March 28, 2014 /PRNewswire/ -- NeuroSigma, Inc.
LONDON, March 27, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
THOUSAND OAKS, Calif., March 26, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast investor meeting at the American College of Cardiology's 63rd Annual Scientific Session (ACC.14)
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.